Owensboro

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Asthma6 trials

Phase

• Phase 35 trials
• Phase 41 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• GlaxoSmithKline6 trials

Running trials

• Recruiting

  A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

  NCT07645248· Phase 3· GlaxoSmithKline· Source

  Contact: Lee Clore (principal investigator)

• Active, not recruiting

  REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

  NCT06041386· Phase 4· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

  NCT05757102· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting

Closed trials

• Completed

  A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

  NCT06261957· Phase 3· GlaxoSmithKline· Source

• Completed

  Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04719832· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source